louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01620125: Metabolic Control Before and After Supplementation With Lactobacillus Reuteri DSM 17938 in Type 2 Diabetes Patients
Official title: Metabolic Control of Type 2 Diabetes Patients Before and After Dietary Supplementation With the Probiotic Lactobacillus Reuteri DSM 17938 - a Pilot Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: EARLY_PHASE1
Conditions: Type 2 Diabetes
Insulin Resistance
Keywords: Lactobacillus
Gut microbiota
Diabetes mellitus
Lead sponsor: Vastra Gotaland Region
Sponsor class: OTHER_GOV
First posted: 2012-06-15
Enrollment: 12
Sex: ALL
Minimum age (years): 50
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Recent data suggest that the trillions of bacteria in the investigators gastrointestinal tracts (gut microbiota) can function as an environmental factor that modulates the amount of body fat. Obese individuals have an altered gut microbiota and germ-free mice are resistant to developing diet-induced obesity and have lower fasting insulin and glucose and improved glucose tolerance. Administration of the probiotic bacterium Lactobacillus strain in fermented milk for 12 weeks reduced adiposity and body weight in obese adults, possibly by reducing lipid absorption and inflammatory status. However, there are no studies to the investigators knowledge that address whether probiotic supplementation improves glucose metabolism in type 2 diabetes patients.


Eligibility criteria: Inclusion Criteria:

* Type 2 diabetes with a duration \> 6 months
* Abdominal obesity
* HbA1c 50-80 mmol/mol
* Written informed consent
* Stated availability throughout the study period

Exclusion Criteria:

* Autoimmune diabetes eg type 1 diabetes
* Psychiatric illness or cancer diagnosis
* No foreseeable need of treatment with corticosteroids or antibiotics
* Inflammatory bowel disease
* Administration of antibiotics 4 weeks before inclusion
* Administration of probiotics 2 weeks before inclusion
* Participation in other clinical trials

Primary outcomes:
measure: HOMA index
timeFrame: 12 weeks
Secondary outcomes:
measure: Changes in diabetes medication and hypoglycemia events
timeFrame: 12 weeks
Other outcomes:
Locations:
city: Gothenburg
country: Sweden
facility: Gothia Forum, CTC, Gröna Stråket 12, Sahlgrenska University Hospital
Study officials:
affiliation: The Wallenberg Laboratory, Bruna Stråket 16, Sahlgrenska University Hospital S-413 45 Gothenburg, Sweden
name: Per-Anders E jansson, Adj prof
role: PRINCIPAL_INVESTIGATOR
affiliation: The Wallenberg Laboratory, Bruna Stråket 16, Sahlgrenska University Hospital, S-413 45 Gothenburg, Sweden
name: Fredrik Bäckhed, Assoc prof
role: STUDY_CHAIR
References:
citation: Backhed F, Manchester JK, Semenkovich CF, Gordon JI. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci U S A. 2007 Jan 16;104(3):979-84. doi: 10.1073/pnas.0605374104. Epub 2007 Jan 8.
Clinical trial NCT00803725: Spinal Mepivicaine With Fentanyl for Outpatient Knee Arthroscopy
Official title: Spinal Mepivicaine With Fentanyl for Outpatient Knee Arthroscopy Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Knee Arthroscopy
Keywords: spinal anesthesia
mepivacaine
fentanyl
duration of anesthesia
knee arthroscopy
regional anesthesia
Spinal anesthesia for knee arthroscopy
Lead sponsor: University Health Network, Toronto
Sponsor class: OTHER
First posted: 2008-12-05
Enrollment: 34
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine if the addition of intrathecal fentanyl to low dose mepivacaine spinal anesthesia provides adequate surgical anesthesia with shorter duration of motor blockade.

It is hypothesized that lower doses of spinal mepivacaine when combined with fentanyl will result in adequate surgical block for knee arthroscopy surgery with faster recovery and discharge compared to mepivacaine alone.


Eligibility criteria: Inclusion Criteria:

1. Patients having unilateral arthroscopic surgery of the knee;
2. ASA I-III status;
3. Age 18-80 years;
4. BMI\< 35.

Exclusion Criteria:

1. Patients who have previous history of hypersensitivity to local anesthetics or contraindications for spinal anesthesia (i.e. bleeding diathesis, coagulopathy);
2. Patients with radiating low back pain and neurological deficits in lower extremities;
3. Patients who are incapable of giving an informed consent.

Primary outcomes:
measure: Time to complete motor block regression (0) as measured by modified Bromage scale.
timeFrame: Every 2 minutes from administration of the spinal until complete onset.
Secondary outcomes:
measure: Block success, peak, and duration; time to ambulation, urination, discharge; incidence of adverse events.
timeFrame: Up to 72 hours after surgery.
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: Toronto Western Hospital
state: Ontario
Study officials:
References:
citation: O'Donnell D, Manickam B, Perlas A, Karkhanis R, Chan VW, Syed K, Brull R. Spinal mepivacaine with fentanyl for outpatient knee arthroscopy surgery: a randomized controlled trial. Can J Anaesth. 2010 Jan;57(1):32-8. doi: 10.1007/s12630-009-9207-6. Epub 2009 Oct 24.
Clinical trial NCT01920425: Kinesia HomeView - Home Diary Comparison
Official title: Kinesia HomeView - Home Diary Comparison
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Parkinson's Disease
Keywords: Parkinson's disease
dyskinesia
fluctuations
tremor
bradykinesia
levodopa
Lead sponsor: Great Lakes NeuroTechnologies Inc.
Sponsor class: INDUSTRY
First posted: 2013-08-12
Enrollment: 2
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: DIAGNOSTIC

Brief summary: The objective is to compare the sensitivity and test-retest reliability of Kinesia HomeView to electronic and hand-written diaries for tracking medication state in the home. Demonstrating comparable or superior results will further support use of the Kinesia HomeView system as an outcome measure in clinical drug trials.


Eligibility criteria: Inclusion Criteria:

* Clinical diagnosis of Parkinson's disease
* On a stable antiparkinsonian medication regimen that includes levodopa for at least 4 weeks
* Experiencing dyskinesia more than 25% of the waking day (score ≥ 2 on Unified Parkinson's Disease Rating Scale item 32)
* With dyskinesias at least moderately disabling (score ≥ 2 on Unified Parkinson's Disease Rating Scale item 33)
* Capable of accurately completing diaries
* Capable of accurately using Kinesia HomeView

Exclusion Criteria:

* Significant medical or psychiatric illness
* Subjects not capable of following the required clinical instructions
* Serious medical conditions that would compromise safety

Primary outcomes:
measure: Test-retest reliability
timeFrame: 4 weeks
Secondary outcomes:
measure: Kinesia HomeView usability questionnaire
timeFrame: After 4 weeks
Other outcomes:
Locations:
city: Valley View
country: United States
facility: Great Lakes NeuroTechnologies Inc
state: Ohio
Study officials:
affiliation: Great Lakes NeuroTechnologies Inc.
name: Dustin A Heldman, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03369925: Cognitive Effects of Citicoline in Men and Women With Age-Associated Memory Impairment
Official title: A Parallel, Double-Blind Study to Assess the Cognitive Effects of a Citicoline Supplement (Cognizin®) in Men and Women With Age-Associated Memory Impairment
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy
Lead sponsor: Kyowa Hakko Bio Co., Ltd.
Sponsor class: INDUSTRY
Collaborators: name: Biofortis Clinical Research, Inc.
First posted: 2017-12-12
Enrollment: 100
Sex: ALL
Minimum age (years): 50
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: The objective of this trial is to determine the effects of citicoline on cognitive performance in healthy Men and Women with Age-Associated Memory Impairment compared to a placebo.

Detailed description: This study is a 12-week, randomized, double-blind, placebo-controlled trial of citicoline in healthy men and women with Age-Associated Memory Impairment. Cognitive assessments will be performed to determine whether citicoline administration with supportive memory, compared to placebo administration.

Eligibility criteria: Inclusion Criteria:

* male or female, 50-85 years of age
* at least a high school diploma or the equivalent
* self-reported memory loss
* scores ≥24 on the Mini-Mental State Examination, ≥85 on the Kaufman Brief Intelligence Test, Second Edition, ≤5 on the Geriatric Depression Scale, and 4, 3, or 2 on the Spatial Span Test
* no health conditions that would prevent him or her from fulfilling the study requirements on the basis of medical history and routine laboratory test results

Exclusion Criteria:

* color blind
* abnormal laboratory test results
* major medical or neurological illness
* female who is pregnant, planning to be pregnant during the study period
* requiring treatment with a drug which might obscure the action of the study treatment

Primary outcomes:
measure: Standardized scores on the Cambridge Brain Sciences that measure cognitive assessment
timeFrame: 12 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Addison
country: United States
facility: Biofortis Clinical Research, Inc.
state: Illinois
Study officials:
References:
citation: Nakazaki E, Mah E, Sanoshy K, Citrolo D, Watanabe F. Citicoline and Memory Function in Healthy Older Adults: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. J Nutr. 2021 Aug 7;151(8):2153-2160. doi: 10.1093/jn/nxab119.
Clinical trial NCT00207025: A Phase I Study of BMS-275183 Given on a Daily Schedule in Patients With Advanced Malignancies
Official title: A Phase I Study of BMS-275183 Given on a Daily Schedule in Patients With Advanced Malignancies
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Tumors
Keywords: Patients with advanced solid tumors
Lead sponsor: Bristol-Myers Squibb
Sponsor class: INDUSTRY
First posted: 2005-09-21
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this clinical research study is to learn about the safety and tolerability of daily BMS-275183 in patients with advanced cancer.


Eligibility criteria: Inclusion Criteria:

* Non-hematologic malignancy that has progressed or no standard therapy is known
* Four weeks from last chemotherapy or two weeks from last non-cytotoxic therapy
* Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1
* No more than 3 prior chemotherapy regimens in advanced/metastatic setting
* Absolute neutrophil count \>=1,500/mm3 and platelets \>=100,000/mm3
* Bilirubin \<=1.5 x Upper Limit of Normal (ULN), Aspartate aminotransferase \<=2.5 x ULN
* Serum creatinine \<=1.5 x ULN
* Men and women \>=18 years
* Women of Child Bearing Potential (WOCBP) must use adequate method of contraception throughout and up to 4 weeks after the study

Exclusion Criteria:

* WOCBP and men not using adequate method of birth control
* WOCBP who are pregnant or breastfeeding
* Prior radiation \>=25% of bone marrow containing skeleton
* Uncontrolled, significant, or active cardiovascular or pulmonary disease or infection or psychiatric disorder
* Neuropathy
* Active brain metastases
* Inability to swallow capsules
* History of gastrointestinal disease, surgery or malabsorption, or requiring use of a feeding tube
* Concurrent chemotherapy, hormonal therapy, immunotherapy, or radiotherapy

Primary outcomes:
measure: Safety and Tolerability
Secondary outcomes:
measure: PK, preliminary evidence of antitumor activity
Other outcomes:
Locations:
city: Detroit
country: United States
facility: Local Institution
state: Michigan
city: Pittsburgh
country: United States
facility: Local Institution
state: Pennsylvania
city: Brussels
country: Belgium
facility: Local Institution
Study officials:
References:
Clinical trial NCT02635425: Aspiration of Limited Number of Follicles to Prevent Severe Ovarian Hyperstimulation Syndrome
Official title: Aspiration of Limited Number of Eggs to Prevent Severe OHSS in Suspected Cases
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Infertility
Lead sponsor: Ain Shams Maternity Hospital
Sponsor class: OTHER
First posted: 2015-12-18
Enrollment: 30
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to evaluate the effect of single ovarian puncture to retrieve 7eggs only in prevention of severe ovarian hyperstimulation syndrome.

Detailed description: Thirty patients will be selected for this study grouped into two groups, each group contains fifteen patients.

Group 1 :study group ( retrieval of 7 eggs only). Group 2 :control group ( retrieval of all eggs). Study is held to compare between the two arms, the proportion of patients who will be prevented from the progression to severe OHSS after this interventional method.

Eligibility criteria: Inclusion Criteria:

1. More than 9 days of induction of ovulation.
2. Each ovary contains more than 20 follicles.
3. The majority of follicles are \>14mm in diameter.
4. Mild fluid in Douglas pouch.
5. The patient started to complain of considerable lower abdominal pains before the egg collection.

Exclusion Criteria:

1. Recurrent ICSI failure or bad obstetric history.
2. Any medical disorder affecting the fluid shift as: diabetes mellitus, autoimmune diseases, hepatic, renal or cardiac conditions.

Primary outcomes:
measure: Number of Participants of Severe Ovarian Hyperstimulation Syndrome
timeFrame: 2 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Ain Shams University
Study officials:
affiliation: Ain Shams University
name: Ahmed H Salama, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04952025: Quantitative Analysis of Precise Brain Volume in Amyotrophic Lateral Sclerosis
Official title: Brain Imaging Study of Amyotrophic Lateral Sclerosis Based on Accurate Brain Volume Quantitative Analysis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Amyotrophic Lateral Sclerosis
Lead sponsor: Peking University Third Hospital
Sponsor class: OTHER
Collaborators: name: Chinese University of Hong Kong
First posted: 2021-07-07
Enrollment: 32
Standard ages: CHILD
ADULT
OLDER_ADULT
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 32

Brief summary: Using the original MRI images of 16 ALS patients and 16 normal controls matched by gender, age and education level in the previous study, the differences of brain volume in different parts of ALS patients and normal controls, and the correlation between brain structure and clinical characteristics were compared by precise brain volume quantitative analysis technology.

Detailed description: This study was a retrospective study. The subjects were 16 ALS patients and 16 normal controls. Previous studies have collected patients' age, gender and education level; The onset site, onset time, bulbar involvement, diagnostic grade, ALSFRS-R score, application of ventilator, application of lirutai, gastrostomy; Age, gender and education level were collected in the control group. Accurate quantitative analysis of brain volume was performed on the original brain MRI images of the two groups.

Eligibility criteria: Inclusion Criteria:

* Diagnosed ALS patients
* healthy volunteers

Exclusion Criteria:

* none

Primary outcomes:
measure: Accurate quantitative analysis of brain volume
timeFrame: 1 day
Secondary outcomes:
measure: general situation
timeFrame: 1 day
Other outcomes:
Locations:
city: Beijing
country: China
facility: Peking University Third Hospital
state: Beijing
Study officials:
affiliation: Peking University Third Hospital
name: Shan Ye
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00452725: Effect of MAXOMAT ® on the Growth of Small Children to NOONAN's Syndrome
Official title: Effect of the Growth Hormone MAXOMAT ® on the Growth of Small Children and Adolescents (<-2 SD) Due to NOONAN's Syndrome
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Noonan Syndrome
Lead sponsor: Sanofi
Sponsor class: INDUSTRY
First posted: 2007-03-27
Enrollment: 36
Sex: ALL
Minimum age (years): 3
Maximum age (years): 15
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: 1. Clinical Objective : To improve the growth of these children
2. Genetic objective : A study of the genetics of the syndrome


Eligibility criteria: Inclusion Criteria:

* Children and adolescents with Noonan's syndrome with a height \< -2 SD and no progressive cardiopathy

Exclusion Criteria:

* Age \< 3 years
* Height ≥ -2 SD

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Primary outcomes:
measure: Evaluation of height : gain in height and rate of growth
timeFrame: at each visit (every 3 months) or every 6 months
Secondary outcomes:
measure: Clinical and laboratory test safety
timeFrame: every 6 months
Other outcomes:
Locations:
city: Paris
country: France
facility: Sanofi-Aventis
Study officials:
affiliation: Sanofi
name: Marie SEBILLE
role: STUDY_DIRECTOR
References:
Clinical trial NCT04537325: Prevention of Acute Kidney Injury After Transcatheter Aortic Valve Implantation
Official title: Prevention of Acute Kidney Injury After Transcatheter Aortic Valve Implantation in Patients With Chronic Kidney Disease With Controlled Intravenous Hydration Matched to Urinary Output
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Acute Kidney Injury
Keywords: Transcatheter aortic valve stenosis
Chronic kidney disease
Acute kidney injury
Lead sponsor: Universitätsklinikum Hamburg-Eppendorf
Sponsor class: OTHER
First posted: 2020-09-03
Enrollment: 98
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Randomized controlled, single-center trial randomizing patients with chronic kidney disease and symptomatic severe aortic valve stenosis undergoing transcatheter aortic valve implantation (TAVI). Patients are randomized in a 1:1 ratio to periprocedural intravenous hydration matched to urine output using the RenalGuard system and to standard hydration. The purpose of the study is to test, wether the controlled intravenous hydration with the RenalGuard system is superior to standard hydration to prevent acute kidney injury after TAVI.

Detailed description: Acute kidney injury (AKI) after transcatheter aortic valve implantation (TAVI) is associated with worse outcome. The RenalGuard system was developed to prevent AKI by a controlled furosemide-induced diuresis with matched isotonic intravenous hydration. It is based on the theory, that a high urinary output prevents contrast media-induced nephropathy (CIN).

The present study is a prospective, randomized trial to investigate wether a matched intravenous hydration using the RenalGuard system is superior to standard pre- and postprocedural intravenous hydration in patients with severe aortic valve stenosis and chronic kidney disease undergoing TAVI. Primary endpoint is the occurrence of AKI after TAVI.

Eligibility criteria: Inclusion Criteria:

* Symptomatic severe aortic valve stenosis undergoing transcatheter aortic valve implantation
* Chronic kidney disease (baseline glomerular filtration rate ≤ 60 ml/min)
* Written informed consent

Exclusion Criteria:

* Hemodynamic instability
* Dialysis-dependent chronic kidney injury
* Emergency transcatheter aortic valve stenosis

Primary outcomes:
measure: Acute kidney injury
timeFrame: Within 7 days after Transcatheter aortic valve implantation
Secondary outcomes:
Other outcomes:
Locations:
city: Hamburg
country: Germany
facility: University Medical Center Hamburg-Eppendorf
Study officials:
affiliation: Universitätsklinikum Hamburg-Eppendorf
name: Ulrich Schäfer, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05755425: CPAP Versus HFNO for the Treatment of Acute Hypoxemic Respiratory Failure Due to Community Acquired Pneumonia
Official title: CPAP Versus High Flow Nasal Cannula Oxygen for the Treatment of Patients With Community Acquired Pneumonia Induced Acute Hypoxemic Respiratory Failure in the Ward
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Pneumonia
Respiratory Failure
Keywords: CPAP
HFNO
Lead sponsor: Evangelismos Hospital
Sponsor class: OTHER
Collaborators: name: University of Thessaly
First posted: 2023-03-06
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult Patients with community acquired pneumonia induced acute hypoxemic respiratory failure that are hospitalized in the common ward and need FiO2 \>50% to keep SpO2 \>93%, or SpO2 \>95% in case of persistent respiratory distress defined as RR\>35/min.

Brief summary: the study compares two non-invasive respiratory support modalities ie CPAP and High Flow nasal cannula oxygen for the treatment of severe hypoxemic respiratory failure attributed to Community acquired Pneumonia.

Detailed description: CPAP and High Flow nasal cannula oxygen are two established modalities for non-invasive respiratory support . In COVID pandemic era both CPAP and HFNO were widely used in the ward for the treatment of COVID-19 induced acute hypoxemic respiratory failure in order to prevent progression to intubation. Head to head comparison between the two modalities mentioned for the treatment of severe hypoxemic respiratory failure is not available neither in COVID pneumonia or Community acquired pneumonia (CAP).

Eligibility criteria: Inclusion Criteria:

* Adult patients with age \>18 year old.
* Been hospitalized with community acquired pneumonia
* hospitalized in common ward (not ICU)
* Patients should have pneumonia- pulmonary infiltrates in chest-xray and hypoxemic respiratory failure.
* Patients should be unable to keep: SpO2\>93% with FiO2 50%, or SpO2 95% with FiO2 50% and have evidence of respiratory distress defined as Respiratory rate -RR\>35/min

Exclusion Criteria:

* Need for immediate or imminent intubation
* not fit for escalation of treatment: defined as intubation, mechanical ventilation and ICU support.
* Pregnant women
* Contraindication to CPAP or HFNO

Primary outcomes:
measure: days free from ventilatory support
timeFrame: 28 days
Secondary outcomes:
measure: treatment failure defined
timeFrame: 28 days
measure: intubation rate
timeFrame: 28 days
measure: hospital mortality
timeFrame: 28 days
measure: days under non-invasive respiratory support
timeFrame: 28 days
measure: hospital length of stay
timeFrame: 28 days
measure: Partial pressure of oxygen PaO2 change at 2h, 12h and 24h
timeFrame: 28 days
Other outcomes:
Locations:
city: Athens
country: Greece
facility: Evaggelismos Hospital
state: Attica
city: Larissa
country: Greece
facility: University General Hospital of Larissa
state: Thesaly
Study officials:
References: